Enrique Grande

List of Publications by Year
in descending order

133 papers	5,161 citations	218677 26 h-index	91884 69 g-index
138 all docs	138 docs citations	138 times ranked	6767 citing authors

#	Article	IF	Citations
1	ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours. Journal of Neuroendocrinology, 2022, 34, e13044.	2.6	14
2	External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study. Neuroendocrinology, 2022, 112, 88-100.	2.5	6
3	Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy. Oncologist, 2022, 27, e328-e339.	3.7	3
4	Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy. Journal of Clinical Medicine, 2022, 11, 497.	2.4	3
5	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. European Urology Focus, 2022, 8, 1696-1702.	3.1	17
6	Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. Clinical Genitourinary Cancer, 2022, 20, 285-295.	1.9	5
7	Re: Effect of Immunotherapy Time-of-day Infusion on Overall Survival Among Patients with Advanced Melanoma in the USA (MEMOIR): A Propensity Score-matched Analysis of a Single-centre, Longitudinal Study. European Urology, 2022, 81, 623-624.	1.9	3
8	Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management. Critical Reviews in Oncology/Hematology, 2022, 174, 103683.	4.4	12
9	High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now?. Current Treatment Options in Oncology, 2022, 23, 1001-1013.	3.0	2
10	Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival. Critical Reviews in Oncology/Hematology, 2022, 176, 103731.	4.4	9
11	Does timing of Immune checkpoint inhibitors (ICIs) administration in first line Metastatic Renal Cell Carcinoma (mRCC) have impact in survival outcomes?. Journal of Clinical Oncology, 2022, 40, e16512-e16512.	1.6	1
12	Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. Clinical Genitourinary Cancer, 2021, 19, e84-e91.	1.9	23
13	Novel Tyrosine Kinase Targets in Urothelial Carcinoma. International Journal of Molecular Sciences, 2021, 22, 747.	4.1	6
14	Coming of Age of Immunotherapy of Urothelial Cancer. Targeted Oncology, 2021, 16, 283-294.	3.6	2
15	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nature Reviews Clinical Oncology, 2021, 18, 313-319.	27.6	103
16	Circulating Levels of the Interferon-Î³-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy. Cancers, 2021, 13, 2849.	3.7	10
17	Sunitinib and Evofosfamide (<scp>TH</scp>-302) in Systemic Treatment-NaÃ¯ve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The <scp>GETNE</scp>-1408 Trial. Oncologist, 2021, 26, 941-949.	3.7	12
18	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Targeted Oncology, 2021, 16, 625-632.	3.6	6

#	Article	IF	Citations
19	Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. Diagnostics, 2021, 11, 138.	2.6	13
20	Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma. Cancers, 2021, 13, 5981.	3.7	31
21	Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy. International Journal of Molecular Sciences, 2020, 21, 4951.	4.1	7
22	In Reply. Oncologist, 2020, 25, e1259-e1259.	3.7	0
23	Patient selection and risk factors in the changing treatment landscape of metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2020, 20, 831-840.	2.4	3
24	Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma treated with cabozantinib and nivolumab. Current Problems in Cancer Case Reports, 2020, 2, 100039.	0.1	2
25	Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2â€drug cocktail in patients with MET â€dysregulated advanced solid tumours: A phase I, multicentre, openâ€label, singleâ€sequence drugâ€“drug interaction study. British Journal of Clinical Pharmacology, 2020, 87, 2867-2878.	2.4	8
26	Chemotherapy Plus Immune Check-Point Inhibitors in Metastatic Bladder Cancer. Bladder Cancer, 2020, 6, 1-8.	0.4	3
27	Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2020, 395, 1547-1557.	13.7	546
28	BRAF Mutated Colorectal Cancer: New Treatment Approaches. Cancers, 2020, 12, 1571.	3.7	44
29	Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2372-2382.	6.4	79
30	The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407). Oncologist, 2020, 25, 745-e1265.	3.7	25
31	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. Clinical Cancer Research, 2020, 26, 2124-2130.	7.0	132
32	Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study.. Journal of Clinical Oncology, 2020, 38, 5011-5011.	1.6	26
33	Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review. World Journal of Gastroenterology, 2020, 26, 4537-4556.	3.3	10
34	Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation. Oncotarget, 2020, 11, 2137-2140.	1.8	2
35	Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). British Journal of Cancer, 2019, 121, 537-544.	6.4	18
36	The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG). Targeted Oncology, 2019, 14, 15-32.	3.6	12

#	Article	IF	Citations
37	Real-World Outcome of 173 Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC) Cases: The Experience of the Center Group for Genitourinary Tumors. Kidney Cancer, 2019, 3, 41-50.	0.4	2
38	Targeting Tyrosine kinases in Renal Cell Carcinoma: â€œNew Bullets against Old Guysâ€• International Journal of Molecular Sciences, 2019, 20, 1901.	4.1	41
39	Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881982821.	3.2	8
40	Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial. Cancer, 2019, 125, 1301-1312.	4.1	68
41	Metaâ€Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors. Oncologist, 2019, 24, e1315-e1320.	3.7	8
42	Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma. Oncologist, 2019, 24, 1375-1383.	3.7	22
43	Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. JCO Precision Oncology, 2019, 3, 1-13.	3.0	15
44	DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.. Journal of Clinical Oncology, 2019, 37, TPS4588-TPS4588.	1.6	5
45	Direct impact of clinical research in metastatic renal cell carcinoma (mRCC): A cost-effectiveness analysis of patient care outcomes and cost savings in a real-life scenario of a large public university hospital in Spain.. Journal of Clinical Oncology, 2019, 37, 637-637.	1.6	3
46	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. European Urology, 2018, 73, 462-468.	1.9	36
47	Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies. Expert Opinion on Drug Safety, 2018, 17, 573-579.	2.4	3
48	Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for â‰¥24 weeks in Europe. European Urology, 2018, 74, 37-45.	1.9	86
49	Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-NaÃ¯ve Advanced Pancreatic Neuroendocrine Tumors. Oncologist, 2018, 23, 766-e90.	3.7	59
50	Inconclusive Analysis of the Connection Between Secondary Hematologic Malignancies and Radioiodine Treatment. Journal of Clinical Oncology, 2018, 36, 1882-1883.	1.6	6
51	A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours. British Journal of Cancer, 2018, 119, 1471-1476.	6.4	74
52	Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours. Cancer Treatment Reviews, 2018, 70, 209-222.	7.7	12
53	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. British Journal of Cancer, 2018, 119, 663-669.	6.4	66
54	Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer. Cancer Treatment Reviews, 2018, 69, 164-176.	7.7	35

#	Article	IF	Citations
55	Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression.. Journal of Clinical Oncology, 2018, 36, 494-494.	1.6	18
56	Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib. Oncotarget, 2018, 9, 36894-36905.	1.8	9
57	Huge recurrent gastric neuroendocrine tumor: a second-line chemotherapeutic dilemma. Autopsy and Case Reports, 2018, 8, e2018005.	0.6	3
58	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	7.7	80
59	Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine, 2017, 376, 125-135.	27.0	2,206
60	Targeting HIF-2 Î± in clear cell renal cell carcinoma: A promising therapeutic strategy. Critical Reviews in Oncology/Hematology, 2017, 111, 117-123.	4.4	90
61	Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer. Best Practice and Research in Clinical Endocrinology and Metabolism, 2017, 31, 295-305.	4.7	43
62	Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting. Therapeutic Advances in Medical Oncology, 2017, 9, 307-318.	3.2	49
63	Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. Critical Reviews in Oncology/Hematology, 2017, 113, 171-190.	4.4	22
64	Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Current Oncology Reports, 2017, 19, 72.	4.0	13
65	Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). European Journal of Endocrinology, 2017, 177, 309-317.	3.7	30
66	Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience. Future Oncology, 2017, 13, 615-624.	2.4	32
67	Emerging use of everolimus in the treatment of neuroendocrine tumors. Cancer Management and Research, 2017, Volume 9, 215-224.	1.9	14
68	Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. Journal of Clinical Oncology, 2017, 35, 14-23.	1.6	258
69	Association of CTC detection by AdnaTest with outcome on enzalutamide in chemotherapy-naÃ¯ve castration-resistant prostate cancer: Exploratory results from PREMIEREâ€"A SOGUG trial.. Journal of Clinical Oncology, 2017, 35, 5052-5052.	1.6	1
70	Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study.. Journal of Clinical Oncology, 2017, 35, 5577-5577.	1.6	1
71	How do patterns of progression influence treatment selection after chemohormonal therapy in patients with metastatic hormone sensitive prostate cancer?. Journal of Clinical Oncology, 2017, 35, e16504-e16504.	1.6	1
72	Adherence to oral therapies in metastatic castration resistance (m CRPC) prostate cancer patients: The ADOPTA study.. Journal of Clinical Oncology, 2017, 35, e18014-e18014.	1.6	3

#	Article	IF	Citations
73	A multicohort phase II study of durvalumab plus tremelimumab for the treatment of patients (PTS) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or lung origin (the) Tj ETQq1 1 0.784314 gBT /Ov	1.6	3
74	Efficacy and safety of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (Abi): A multicenter, single-arm, open-label study.. Journal of Clinical Oncology, 2017, 35, 165-165.	1.6	1
75	Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy.. Journal of Clinical Oncology, 2017, 35, 323-323.	1.6	4
76	Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate. World Journal of Clinical Oncology, 2017, 8, 100.	2.3	14
77	A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).. Journal of Clinical Oncology, 2017, 35, 285-285.	1.6	0
78	Association of androgen receptor (AR) gene status in plasma DNA with outcome on enzalutamide in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Exploratory results from the PREMIERE trialâ€"On behalf of SOGUG.. Journal of Clinical Oncology, 2017, 35, 5016-5016.	1.6	0
79	Association of weight change with telotristat ethyl in the treatment of carcinoid syndrome.. Journal of Clinical Oncology, 2017, 35, e15692-e15692.	1.6	0
80	Living with Cancer: Through the Eyes of the Patient and the Physician. Oncology and Therapy, 2016, 4, 183-187.	2.6	0
81	Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors. Oncologist, 2016, 21, 701-707.	3.7	22
82	Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations. Targeted Oncology, 2016, 11, 129-141.	3.6	3
83	Spanish consensus for the management of patients with advanced radioactive iodine refractory differentiated thyroid cancer. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2016, 63, e17-e24.	0.8	18
84	Regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy (PChT) patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD).. Journal of Clinical Oncology, 2016, 34, 3527-3527.	1.6	3
85	Updated efficacy and > 1-y follow up from IMvigor210: Atezolizumab (atezo) in platinum (plat) treated locally advanced/metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2016, 34, 4515-4515.	1.6	12
86	Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2016, 34, 4557-4557.	1.6	4
87	Efficacy of multikinase inhibitors (MKIs) in successive treatment lines of refractory advanced thyroid cancer patients (pts).. Journal of Clinical Oncology, 2016, 34, e17553-e17553.	1.6	1
88	A phase II trial to assess the activity and safety of the hypoxia-activated prodrug evofosfamide (TH-302) in combination with sunitinib in patients with disseminated grade 1 and 2 pancreatic neuroendocrine tumors (pNET) as a first-line approach: The GETNE-1408 trial.. Journal of Clinical Oncology, 2016, 34, TPS479-TPS479.	1.6	2
89	Sequential treatment in disseminated well- and intermediate-differentiated pancreatic neuroendocrine tumors: Common sense or low rationale?. World Journal of Clinical Oncology, 2016, 7, 149.	2.3	1
90	Impact of previous abiraterone acetate treatment in docetaxel safety profile: Preliminary results of the randomized phase II ABIDO-SOGUG trial.. Journal of Clinical Oncology, 2016, 34, 5058-5058.	1.6	0

#	Article	IF	Citations
91	Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study.. Journal of Clinical Oncology, 2016, 34, TPS2598-TPS2598.	1.6	0
92	Primary Sarcomatoid Tumor of the Bladder: A Different Entity but the Same Approach?. Clinical Genitourinary Cancer, 2015, 13, 493-498.	1.9	7
93	Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer and Metastasis Reviews, 2015, 34, 823-842.	5.9	39
94	An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs). Rare Cancers and Therapy, 2015, 3, 13-33.	0.2	4
95	Consensus on the management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI). Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2015, 62, e37-e46.	0.8	6
96	Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer, 2015, 15, 495.	2.6	25
97	Randomized phase II study of abiraterone acetate (AA) maintenance in combination with docetaxel after disease progression to AA in metastatic castration resistant prostate cancer (mCRPC): Preliminary safety results of first line AA treatmentâ€"ABIDO-SOGUG Trial.. Journal of Clinical Oncology, 2015, 33, e16022-e16022.	1.6	1
98	Prognostic factors in advanced gastric cancer after second-line treatment.. Journal of Clinical Oncology, 2015, 33, 201-201.	1.6	0
99	Tumor markers as predictors of outcome in patients with advanced esophagogastric adenocarcinoma (EGA) treated with chemotherapy.. Journal of Clinical Oncology, 2015, 33, e15061-e15061.	1.6	0
100	Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of response to enzalutamide in patients with metastatic castration resistant prostate cancer (CRPC) pre-chemotherapy: PREMIERE-SOGUG Trial.. Journal of Clinical Oncology, 2015, 33, TPS5073-TPS5073.	1.6	0
101	Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II studyâ€"GETHI 2013-01.. Journal of Clinical Oncology, 2015, 33, TPS5612-TPS5612.	1.6	1
102	Preliminary safety results of regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD).. Journal of Clinical Oncology, 2015, 33, e14524-e14524.	1.6	1
103	Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer, 2014, 14, 779.	2.6	33
104	Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. Cancer Treatment Reviews, 2014, 40, 1230-1238.	7.7	34
105	What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?. Critical Reviews in Oncology/Hematology, 2014, 92, 83-106.	4.4	30
106	Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).. Journal of Clinical Oncology, 2014, 32, 6027-6027.	1.6	2
107	Correlation of VEGFR2 expression in tumor tissue with longer progression-free survival in patients with neuroendocrine tumors (NETs) treated with pazopanib.. Journal of Clinical Oncology, 2014, 32, e15154-e15154.	1.6	3
108	Potential prognostic and predictive factors in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) in daily clinical practice in Spain.. Journal of Clinical Oncology, 2014, 32, e16074-e16074.	1.6	1

#	Article	IF	Citations
109	A phase 1b study of the anticancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) with or without paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 279-279.	1.6	5
110	A Comprehensive Review of Poorly Differentiated Neuroendocrine Carcinomas (pdNECs): a Niche to Find Novel Opportunities. Current Pharmaceutical Design, 2014, 20, 6644-6651.	1.9	3
111	Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract (TCCU) after failure to one cisplatin-based systemic therapy in clinical practice.. Journal of Clinical Oncology, 2014, 32, 332-332.	1.6	0
112	Regorafenib as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC): A study of the Spanish Cooperative Group for digestive tumor therapy (TTD).. Journal of Clinical Oncology, 2014, 32, TPS3651-TPS3651.	1.6	1
113	Study of the gastroenteropancreatic neuroendocrine tumor (gep-net) microenvironment beyond angiogenesis: The role of lysyl oxidase-like 2 (LOXL2).. Journal of Clinical Oncology, 2014, 32, 4109-4109.	1.6	0
114	Pazopanib activity in pancreatic neuroendocrine tumors (pNETs).. Journal of Clinical Oncology, 2014, 32, e15171-e15171.	1.6	0
115	Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study.. Journal of Clinical Oncology, 2014, 32, TPS5626-TPS5626.	1.6	0
116	Soft tissue sarcomas: A challenge for oncology.. Journal of Clinical Oncology, 2014, 32, e21512-e21512.	1.6	0
117	Ketoconazole as inhibitor of the enzyme CYP17 in locally advanced or disseminated granulosa cell tumors of the ovary (the GreKo I study) (gethi 11-03).. Journal of Clinical Oncology, 2014, 32, 5558-5558.	1.6	0
118	Retrospective analysis of the safety and efficacy of vandetanib as systemic treatment for patients with advanced and progressive medullary thyroid cancer (MTC).. Journal of Clinical Oncology, 2014, 32, e17015-e17015.	1.6	0
119	Randomized phase II study of abiraterone acetate maintenance in combination with docetaxel after disease progression to abiraterone acetate in metastatic castration-resistant prostate cancer (mCRPC): ABIDO SOGUG trial.. Journal of Clinical Oncology, 2014, 32, TPS5096-TPS5096.	1.6	0
120	Survival surrogates in gastric cancer after first- and second-line chemotherapy treatment: A Spanish retrospective study from one institution.. Journal of Clinical Oncology, 2014, 32, e15019-e15019.	1.6	0
121	sVEGFR2 and circulating tumor cells to predict for the efficacy of pazopanib in neuroendocrine tumors (NETs): PAZONET subgroup analysis.. Journal of Clinical Oncology, 2013, 31, 4140-4140.	1.6	17
122	Molecular characterization of nonpancreatic neuroendocrine neoplasms (NENS): First description of mutations in the tumor suppressor gene (TSG) SMARCB1 in NENS of colorectal origin using next-generation sequencing (NGS).. Journal of Clinical Oncology, 2013, 31, 4135-4135.	1.6	0
123	Epithelial-mesenchymal transition markers in metastatic transitional cell carcinoma (mTCC) patients under vinflunine treatment.. Journal of Clinical Oncology, 2013, 31, e15532-e15532.	1.6	0
124	Temozolamide plus capecitabine as salvage treatment for patients with advanced neuroendocrine tumors (NETs) in the community setting.. Journal of Clinical Oncology, 2013, 31, e15169-e15169.	1.6	1
125	A significant response to sunitinib in a patient with anaplastic thyroid carcinoma. Journal of Research in Medical Sciences, 2013, 18, 623-5.	0.9	17
126	Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies. Journal of Thyroid Research, 2012, 2012, 1-10.	1.3	48

#	Article	IF	Citations
127	New targeted approaches against the ubiquitinâ€“proteasome system in gastrointestinal malignancies. Expert Review of Anticancer Therapy, 2012, 12, 457-467.	2.4	7
128	Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?. Cancer and Metastasis Reviews, 2012, 31, 47-53.	5.9	17
129	Evaluation of safety and efficacy of somatuline autogel in combination with molecular targeted therapies (MTT) in patients with neuroendocrine tumors (NETs): Data from one Spanish cohort.. Journal of Clinical Oncology, 2012, 30, e14671-e14671.	1.6	2
130	Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor. Anti-Cancer Drugs, 2011, 22, 477-479.	1.4	8
131	Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain. Clinical and Translational Oncology, 2011, 13, 798-804.	2.4	4
132	Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment. Molecular Cancer Therapeutics, 2011, 10, 569-579.	4.1	99
133	Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs). Clinical and Translational Oncology, 2010, 12, 481-492.	2.4	5